Investigational drug · Phase 2
CIL001
Also called: paliroden
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cochlear Synaptopathy, Tinnitus, Bilateral.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "CIL001"
First trial start
2027
Jan 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CIL001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cochlear Synaptopathy
- Tinnitus, Bilateral
Largest trials
Live from ClinicalTrials.gov: studies naming "CIL001" as an intervention, largest first.
- A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy SituationsPivotal-lookingNot yet recruiting
Cilcare SASIndustry
NCT07472907 · 135 participants (planned) · Start Jan 2027 · Primary completion Dec 2027
Drug: CIL001 (Paliroden); Placebo · For: Cochlear Synaptopathy
- A Study Testing Safety and Efficacy of Transtympanic Paliroden for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant TinnitusNot yet recruiting
Cilcare SASIndustry
NCT07826507 · 60 participants (planned) · Start Jan 2027 · Primary completion Jan 2028
Drug: paliroden (CIL001); Placebo · For: Tinnitus, Bilateral; Cochlear Synaptopathy
Newest research
PubMed records naming it or its code names, newest first.
- Effects of paliroden (SR57667B) and xaliproden on adult brain neurogenesis.
Labie C, Canolle B, Chatelin S, et al. · Curr Alzheimer Res 2006
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.